Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-77c89778f8-fv566 Total loading time: 0 Render date: 2024-07-18T16:24:09.275Z Has data issue: false hasContentIssue false

Chapter 21 - Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy

from Section 5 - Psychopharmacology

Published online by Cambridge University Press:  19 October 2021

By
Debbi A. Morrissette  and
Stephen M. Stahl
Edited by
Katherine D. Warburton  and
Stephen M. Stahl
Katherine D. Warburton
Affiliation:
University of California, Davis
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Violence in Psychiatry , pp. 221 - 233
Publisher: Cambridge University Press
Print publication year: 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Stahl, SM, Morrissette, DA, Citrome, L, et al. “Meta-guidelines” for the management of patients with schizophrenia. CNS Spectr. 2013; 18(3): 150–162.Google Scholar
Stahl, SM. Emerging guidelines for the use of antipsychotic polypharmacy. Rev. Psiquiatr. Salud Ment. 2013; 6(3): 97–100.Google Scholar
Citrome, L, Volavka, J. Pharmacological management of acute and persistent aggression in forensic psychiatry settings. CNS Drugs. 2011; 25(12): 1009–1021.Google Scholar
Warburton, K. The new mission of forensic mental health systems: managing violence as a medical syndrome in an environment that balances treatment and safety. CNS Spectr. 2014; 0(5): 368–373.CrossRefGoogle Scholar
Nolan, KA, Czobor, P, Roy, BB, et al. Characteristics of assaultive behavior among psychiatric inpatients. Psychiatr. Serv. 2003; 54(7): 1012–1016.Google Scholar
Volavka, J, Citrome, L. Heterogeneity of violence in schizophrenia and implications for long-term treatment. Int. J. Clin. Pract. 2008; 62 (8): 1237–1245.Google Scholar
Volavka, J, Citrome, L. Pathways to aggression in schizophrenia affect results of treatment. Schizophr. Bull. 2011; 37(5): 921–929.Google Scholar
Swanson, JW, Swartz, MS, Van Dorn, RA, et al. Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. Br. J. Psychiatry. 2008; 193(1): 37–43.Google Scholar
Quanbeck, CD, McDermott, BE, Lam, J, et al. Categorization of aggressive acts committed by chronically assaultive state hospital patients. Psychiatr. Serv. 2007; 58(4): 521–528.Google Scholar
Stahl, SM. Stahl's Essential Psychopharmacology, 4th edn. New York: Cambridge University Press; 2013.Google Scholar
Stahl, SM, Morrissette, DA. Stahl's Illustrated Violence: Neural Circuits, Genetics, and Treatment. New York: Cambridge University Press; 2014.Google Scholar
Siever, LJ. Neurobiology of aggression and violence. Am. J. Psychiatry. 2008; 165(4): 429–442.Google Scholar
Frogley, C, Taylor, D, Dickens, G, Picchioni, M. A systematic review of the evidence of clozapine's anti-aggressive effects. Int. J. Neuropsychopharmacol. 2012; 15(9): 1351–1371.CrossRefGoogle ScholarPubMed
Coccaro, EF, McCloskey, MS, Fitzgerald, DA, Phan, KL. Amygdala and orbitofrontal reactivity to social threat in individuals with impulsive aggression. Biol. Psychiatry. 2007; 62(2): 168–178.Google Scholar
Coccaro, EF, Sripada, CS, Yanowitch, RN, Phan, KL. Corticolimbic function in impulsive aggressive behavior. Biol. Psychiatry. 2011; 69(12): 1153–1159.Google Scholar
Bobes, J, Fillat, O, Arango, C. Violence among schizophrenia out-patients compliant with medication: prevalence and associated factors. Acta Psychiatr. Scand. 2009; 119(3): 218–225.CrossRefGoogle ScholarPubMed
Meyer, J. A rational approach to employing high plasma levels of antipsychotics for violence associated with schizophrenia: case vignettes. CNS Spectr. 2014; 19(5): 432–438. DOI: http://dx.doi.org/10.1017/ S1092852914000236.Google Scholar
Stahl, SM. Antipsychotic polypharmacy: never say never, but never say always. Acta Psychiatr. Scand. 2012; 125(5): 349–351.Google Scholar
Pavlov, KA, Chistiakov, DA, Chekhonin, VP. Genetic determinants of aggression and impulsivity in humans. J. Appl. Genet. 2012; 53(1): 61–82.Google Scholar
Fazel, S, Grann M, Langstrom N. What is the role of epidemiology for forensic psychiatry? Crim. Behav. Ment. Health. 2009; 19(5): 281–285.CrossRefGoogle ScholarPubMed
Fazel, S, Gulati, G, Linsell, L, Geddes, JR, Grann, M. Schizophrenia and violence: systematic review and meta-analysis. PLoS Med. 2009; 6 (8): e1000120.Google Scholar
Fazel, S, Langstrom, N, Hjern, A, Grann, M, Lichtenstein, P. Schizophrenia, substance abuse, and violent crime. JAMA. 2009; 301(19): 2016–2023.Google Scholar
Topiwala, A, Fazel, S. The pharmacological management of violence in schizophrenia: a structured review. Expert Rev. Neurother. 2011; 11(1): 53–63.CrossRefGoogle ScholarPubMed
Krakowski, MI, Czobor, P. Executive function predicts response to antiaggression treatment in schizophrenia: a randomized controlled trial. J. Clin. Psychiatry. 2012; 73(1): 74–80.CrossRefGoogle ScholarPubMed
Krakowski, MI, Czobor, P, Nolan, KA. Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients. J. Clin. Psychopharmacol. 2008; 28(5): 485–493.Google Scholar
Singh, JP, Grann, M, Fazel, S. A comparative study of violence risk assessment tools: a systematic review and metaregression analysis of 68 studies involving 25,980 participants. Clin. Psychol. Rev. 2011; 31(3): 499–513.Google Scholar
Song, H, Min, SK. Aggressive behavior model in schizophrenic patients. Psychiatry Res. 2009; 167(1–2): 58–65.Google Scholar
Uchida, H, Takeuchi, H, Graff-Guerrero, A, et al. Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis. J. Clin. Psychopharmacol. 2011; 31(4): 497–502.Google Scholar
Correll, CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur. Psychiatry. 2010; 25(Suppl 2): S12–S21.Google Scholar
Nord, M, Farde, L. Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neurosci. Ther. 2011; 17(2): 97–103.Google Scholar
Uchida, H, Takeuchi, H, Graff-Guerrero, A, et al. Predicting dopamine D receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis. J. Clin. Psychopharmacol. 2011; 31(3): 318–325.Google Scholar
Stauffer, V, Case, M, Kollack-Walker, S, et al. Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials. Schizophr. Res. 2011; 130(1–3): 11–19.Google Scholar
Robinson, DG, Woerner, MG, Alvir, JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am. J. Psychiatry. 1999; 156(4): 544–549.Google Scholar
Stahl, SM. Stahl's Essential Psychopharmacology, 3rd edn. New York: Cambridge University Press; 2008.Google Scholar
Morrissette, DA, Stahl, SM. Optimizing outcomes in schizophrenia: long-acting depots and long-term treatment. CNS Spectr. 2012; 17 (Suppl 1): 10–21.Google Scholar
Ritsner, MS, ed. Polypharmacy in Psychiatric Practice, Volume I: Multiple Medication Use Strategies. New York: Springer Verlag; 2013.Google Scholar
Ritsner, MS, ed. Polypharmacy in Psychiatric Practice, Volume II: Use of Polypharmacy in the "Real World". New York: Springer Verlag; 2013.Google Scholar
Stentebjerg-Olesen, M, Jeppesen, P, Pagsberg, AK, et al. Early nonresponse determined by the Clinical Global Impressions scale predicts poorer outcomes in youth with schizophrenia spectrum disorders naturalistically treated with second-generation antipsychotics. J. Child Adolesc. Psychopharmacol. 2013; 23(10): 665–675.Google Scholar
Mauri, MC, Volonteri, LS, Colasanti, A, et al. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin. Pharmacokinet. 2007; 46(5): 359–388.Google Scholar
Remington, G, Kapur, S. Antipsychotic dosing: how much but also how often? Schizophr. Bull. 2010; 36(5): 900–903.Google Scholar
Samaha, AN, Seeman, P, Stewart, J, Rajabi, H, Kapur, S. “Breakthrough” dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J. Neurosci. 2007; 27(11): 2979–2986.CrossRefGoogle ScholarPubMed
Seeman, P. Dopamine D2 receptors as treatment targets in schizophrenia. Clin. Schizophr. Relat. Psychoses. 2010; 4(1): 56–73.Google Scholar
Davis, JM, Chen, N. Dose response and dose equivalence of antipsychotics. J. Clin. Psychopharmacol. 2004; 24(2): 192–208.Google Scholar
Krakowski, MI, Kunz, M, Czobor, P, Volavka, J. Long-term high-dose neuroleptic treatment: who gets it and why? Hosp. Community Psychiatry. 1993; 44(7): 640–644.Google Scholar
Gisev, N, Bell, JS, Chen, TF. Factors associated with antipsychotic polypharmacy and high-dose antipsychotics among individuals receiving compulsory treatment in the community. J. Clin. Psychopharmacol. 2014; 34(3): 307–312.Google Scholar
Roh, D, Chang, JG, Kim, CH, et al. Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison. Aust. N. Z. J. Psychiatry. 2014; 48(1): 52–60.Google Scholar
Barnes, TR, Paton, C. Antipsychotic polypharmacy in schizophrenia: benefits and risks. CNS Drugs. 2011; 25(5): 383–399.Google Scholar
Fleischhacker, WW, Uchida, H. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. Int. J. Neuropsychopharmacol. 2014; 17(7): 1083–1093.Google Scholar
Fujita, J, Nishida, A, Sakata, M, Noda, T, Ito, H. Excessive dosing and polypharmacy of antipsychotics caused by prorenata in agitated patients with schizophrenia. Psychiatry Clin. Neurosci. 2013; 67(5): 345–351.Google Scholar
Gallego, JA, Bonetti, J, Zhang, J, Kane, JM, Correll, CU. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr. Res. 2012; 138(1): 18–28.Google Scholar
Lochmann van Bennekom, MWH, Gijsman, HJ, Zitman, FG. Antipsychotic polypharmacy in psychotic disorders: a critical review of neurobiology, efficacy, tolerability and cost effectiveness. J. Psychopharmacol. 2013; 27(4): 327–336.Google Scholar
Sagud, M, Vuksan-Cusa, B, Zivkovic, M, et al. Antipsychotics: to combine or not to combine? Psychiatr. Danub. 2013; 25(3): 306–310.Google ScholarPubMed
Suokas, JT, Suvisaari, JM, Haukka, J, Korhonen, P, Tiihonen, J. Description of long-term polypharmacy among schizophrenia outpatients. Soc. Psychiatry Psychiatr. Epidemiol. 2013; 48(4): 631–638.Google Scholar
Freudenreich, O, Goff, DC. Antipsychotic combination therapy in schizophrenia: a review of efficacy and risks of current combinations. Acta Psychiatr. Scand. 2002; 106(5): 323–330.Google Scholar
Goren, JL, Meterko, M, Williams, S, et al. Antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia. Psychiatr. Serv. 2013; 64(6): 527–533.Google Scholar
Englisch, S, Zink, M. Treatment-resistant schizophrenia: evidence-based strategies. Mens Sana Monogr. 2012; 10(1): 20–32.Google Scholar
Langle, G, Steinert, T, Weiser, P, et al. Effects of polypharmacy on outcome in patients with schizophrenia in routine psychiatric treatment. Acta Psychiatr. Scand. 2012; 125(5): 372–381.CrossRefGoogle ScholarPubMed
Essock, SM, Schooler, NR, Stroup, TS, et al. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am. J. Psychiatry. 2011; 168(7): 702–708.Google Scholar
Stahl, SM, Grady, MM. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr. Med. Chem. 2004; 11(3): 313–327.Google Scholar
Stahl, SM. Focus on antipsychotic polypharmacy: evidence-based prescribing or prescribing-based evidence? Int. J. Neuropsychopharmacol. 2004; 7(2): 113–116.Google Scholar
Stahl, SM. Antipsychotic polypharmacy: evidence based or eminence based? Acta Psychiatr. Scand. 2002; 106(5): 321–322.Google Scholar
Stahl, SM. Antipsychotic polypharmacy: squandering precious resources? J. Clin. Psychiatry. 2002; 63(2): 93–94.Google Scholar
Stahl, SM. Antipsychotic polypharmacy, part 2: tips on use and misuse. J. Clin. Psychiatry. 1999; 60(8): 506–507.Google Scholar
Stahl, SM. Antipsychotic polypharmacy, part 1: therapeutic option or dirty little secret? J. Clin. Psychiatry. 1999; 60(7): 425–426.Google Scholar
Stahl, SM. “Awakening” from schizophrenia: intramolecular polypharmacy and the atypical antipsychotics. J. Clin. Psychiatry. 1997; 58(9): 381–382.Google Scholar
Suzuki, T, Uchida, H, Tanaka, KF, et al. Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia. Int. J. Neuropsychopharmacol. 2004; 7(2): 133–142.CrossRefGoogle ScholarPubMed
Correll, CU, Rummel-Kluge, C, Corves, C, Kane, JM, Leucht, S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr. Bull. 2009; 35(2): 443–457.Google Scholar
Iasevoli, F, Buonaguro, EF, Marconi, M, et al. Efficacy and clinical determinants of antipsychotic polypharmacy in psychotic patients experiencing an acute relapse and admitted to hospital stay: results from a cross-sectional and a subsequent longitudinal pilot study. ISRN Pharmacology. 2014; 2014: 762127.Google Scholar
Coccaro, EF. Intermittent explosive disorder as a disorder of impulsive aggression for DSM-5. Am. J. Psychiatry. 2012; 169(6): 577–588.Google Scholar
Rosell, DR, Thompson, JL, Slifstein, M, et al. Increased serotonin 2A receptor availability in the orbitofrontal cortex of physically aggressive personality disordered patients. Biol. Psychiatry. 2010; 67(12): 1154–1162.Google Scholar
Winstanley, CA, Theobald, DE, Dalley, JW, Glennon, JC, Robbins, TW. 5-HT2A and 5-HT2C receptor antagonists have opposing effects on a measure of impulsivity: interactions with global 5-HT depletion. Psychopharmacology (Berl.). 2004; 176(3–4): 376–385.Google Scholar
Englisch, S, Zink, M. Combined antipsychotic treatment involving clozapine and aripiprazole. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2008; 32(6): 1386–1392.CrossRefGoogle ScholarPubMed
Katona, L, Czobor, P. Bitter I. Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: to switch or to combine? A nationwide study in Hungary. Schizophr. Res. 2014; 152(1): 246–254.Google Scholar
Ballon, J, Stroup, TS. Polypharmacy for schizophrenia. Curr. Opin. Psychiatry. 2013; 26(2): 208–213.Google Scholar
Fleischhacker, WW, Heikkinen, ME, Olie, JP, et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int. J. Neuropsychopharmacol. 2010; 13(8): 1115–1125.Google Scholar
Chang, JS, Ahn, YM, Park, HJ, et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry. 2008; 69(5): 720–731.Google Scholar
Thompson, C. The use of high-dose antipsychotic medication. Br. J. Psychiatry. 1994; 164(4): 448–458.Google Scholar
Schwartz, TL, Stahl, SM. Treatment strategies for dosing the second generation antipsychotics. CNS Neurosci. Ther. 2011; 17(2): 110–117.Google Scholar
Volavka, J, Czobor, P, Nolan, K, et al. Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. J. Clin. Psychopharmacol. 2004; 24(2): 225–228.CrossRefGoogle ScholarPubMed
Kantrowitz, JT, Citrome, L. Lurasidone for schizophrenia: what's different? Expert Rev. Neurother. 2012; 12(3): 265–273.Google Scholar
Aggarwal, NK, Sernyak, MJ, Rosenheck, RA. Prevalence of concomitant oral antipsychotic drug use among patients treated with long-acting, intramuscular, antipsychotic medications. J. Clin. Psychopharmacol. 2012; 32(3): 323–328.CrossRefGoogle ScholarPubMed
Elie, D, Poirier, M, Chianetta, J, et al. Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder. J. Psychopharmacol. 2010; 24(7): 1037–1044.Google Scholar
Hiemke, C, Baumann, P, Bergemann, N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry. 2011; 44(6): 195–235.Google ScholarPubMed
Potkin, SG, Keator, DB, Kesler-West, ML, et al. D2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder. CNS Spectr. 2014; 19(2): 176–181.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×